

Disclosure and Resolution of Personal Conflicts of Interest

In accordance with CME/CPD accreditation criteria and standards for commercial support to ensure balance, independence, objectivity, and scientific rigor in CME/CPD activities, those in control of the educational content must disclose potential or actual conflicts of interest, whether due to a financial or other relationship. Disclosure information is evaluated and conflicts of interest resolved. Disclosure is made to participants prior to the activity. Participants will be asked in the evaluation to assess the objectivity and independence of the event. Off-label or investigational use of a therapeutic product is also disclosed.

Last Name	First Name	Role(s)	Relationship(s)	Company	Honoraria/ Expenses	Consulting/ Advisory Board	Funded Research	Royalties/ Patent	Stock Options	Ownership/ Equity Position	Employee	Other	Off-Label Product Use
Aithal	Guruprasad	Invited Speaker/ Faculty	No										
Boursier	Jerome	Invited Speaker/ Faculty	Yes	Echosens	x								
				Intercept		x							
				Gilead		x							
				BMS		x							
Castera	Laurent	Invited Speaker/ Faculty	Yes	Allergan		x							
				Gilead	x	x							
				Intercept	x	x							
				MSD		x							
				Pfizer		x							
				Servier		x							
				Abbvie	x								
				Echosens	x								
				Sirtex	x								
Castiella	Agustin	Poster/ Oral Presenter	No										
Sunil	Dadhich	Poster/ Oral Presenter	No										Saroglitazar in NAFLD
Dufour	Jean-Francois	Invited Speaker/ Faculty	Yes	Bayer	x	x							
				BMS		x							
				Gilead		x							
				Intercept		x							
				Janssen Cilag		x							
				Merck		x							
				Novartis		x							
				Roche		x							
				Can Fite									
Fishman	Pnina	Poster/ Oral Presenter	Yes	BioPharma					x		x		
Heikenwaelder	Mathias	Invited Speaker/ Faculty	No										
Kahl	Sabine	Poster/ Oral Presenter	No										
Kaps	Leonard	Poster/ Oral Presenter	No										
Kowdley	Kris	Invited Speaker/ Faculty	Yes	Allergan		x	x						Cenicriviroc, GS-4997, GS-0976, Obeticholic acid, INT-747, Saroglitazar Mg, Emricasan, EDP-305
				Conatus		x	x						
				Corcept		x							

Last Name	First Name	Role(s)	Relationship(s)	Company	Honoraria/ Expenses	Consulting/ Advisory Board	Funded Research	Royalties/ Patent	Stock Options	Ownership/ Equity Position	Employee	Other	Off-Label Product Use
				Enanta		x							
				Gilead	x		x						
				Intercept	x		x						
				Prometheus			x						
				Zydus Discovery			x						
Lazarus	Jeffrey	Invited Speaker/ Faculty	Yes	Abbvie	x	x	x						
				Gilead	x	x	x						
				Janssen		x							
				MSD	x	x	x						
Milgrom	Yael	Poster/ Oral Presenter	No										
Mueller	Sebastian												
Muller-Wieland	Dirk	Invited Speaker	Yes	Astrazeneca	x	x							
				Boehringer Ingelheim	x	x							
				Sanofi	x	x							
				Novo Nordisk	x	x							
				MSD	x	x							
Neubauer	Stefan	Invited Speaker/ Faculty & Session Chair	Yes	Perspectum Diagnostics		x				x			Will discuss some recent NASH trials, e.g. NGM and Madrigal
				Caristo Diagnostics		x				x			
Newsome	Philip	Invited Speaker/ Faculty & Session Chair	Yes	Gilead		x							
				Novo Nordisk		x	x						
				Pfizer		x							
				Boehringer ingelheim		x	x						
				Affimmune		x							
				Intercept		x							
Oliveira	Claudia	Invited Speaker/ Faculty	No										
Perseghin	Gianluca	Invited Speaker/ Faculty & Session Chair											
Petta	Salvatore	Invited Speaker/ Faculty & Session Chair											
Porras	David	Poster/ Oral Presenter	No										
Reeves	Helen	Invited Speaker/ Faculty	Yes	Eisai		x							
				Bayer	x								
				MSD	x								
				Medivir			x						
Romero Gomez	Manuel	Invited Speaker/ Faculty & Session Chair	Yes	Intercept	x	x	x						
				Gilead	x	x	x						

Last Name	First Name	Role(s)	Relationship(s)	Company	Honoraria/ Expenses	Consulting/ Advisory Board	Funded Research	Royalties/ Patent	Stock Options	Ownership/ Equity Position	Employee	Other	Off-Label Product Use
				Allergan		x							
Schattenberg	Jörn	Invited Speaker/ Faculty & Session Chair	Yes	Boehringer Ingelheim		x							
				Intercept Pharmaceuticals		x							
				Genfit		x							
				Gilead Sciences		x	x						
				AbbVie		x							
				BMS		x							
				MedImmune		x							
				Novartis		x							
				Pfizer		x							
				Humedics			x						
				Yakult Europe B.V.			x						
Schuppan	Detlef	Invited Speaker/ Faculty	No										
Serfaty	Lawrence	Invited Speaker/ Faculty & Session Chair	Yes	Intercept	x	x							
				Gilead	x	x							
				Pfizer	x	x							
				Novartis	x	x							
				Allergan	x	x							
Tacke	Frank	Invited Speaker/ Faculty	Yes	BMS (Bristol-Myers Squibb)			x						
				Allergan		x	x						
				Inventiva		x	x						
				Galapagos			x						
				Boehringer		x							
Trauner	Michael	Invited Speaker/ Faculty	Yes	Falk Pharma		x	x					Travel grants, Speaker Bureau	FXR ligands, FGF 19 mimetics, nor- UDCA
				Phenex		x							
				Albireo		x	x						
				Novartis		x							
				Gilead		x						Speaker bureau, Travel grants	
				MSD		x	x					Speaker bureau	
				Intercept		x	x						
				BMS (Bristol-Myers Squibb)		x							
				Regulus		x							
				Roche								Speaker bureau, Travel grants	

Last Name	First Name	Role(s)	Relationship(s)	Company	Honoraria/ Expenses	Consulting/ Advisory Board	Funded Research	Royalties/ Patent	Stock Options	Ownership/ Equity Position	Employee	Other	Off-Label Product Use
				Takeda			x						
								x				Co-Inventor Patent on Medical use of nor- UDCA	
Walker	Mark	Invited Speaker/ Faculty	No										
Younes	Ramy	Invited Speaker/ Faculty & Session Chair	No										
Younossi	Zobair	Invited Speaker/ Faculty & Session Chair	Yes	Gilead Sciences		x							
				Intercept		x							
				BMS		x							
				Novo Nordisk		x							
				Viking		x							
				Abbvie		x							
				Shinogi		x							
				Terns		x							
				Novartis		x							
				Merck		x							
Zaharia	Oana Patricia	Poster/ Oral Presenter	No										
Zelber Sagi	Shira	Invited Speaker/ Faculty	No										